Uniphar PLC
ISEQ:UPR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
U
|
Uniphar PLC
ISEQ:UPR
|
IE |
|
Aohata Corp
TSE:2830
|
JP |
|
D
|
DoanXa Port JSC
VN:DXP
|
VN |
|
A
|
Alloggio Pty Ltd
ASX:ALO
|
AU |
|
Kaplamin Ambalaj Sanayi ve Ticaret AS
IST:KAPLM.E
|
TR |
|
T
|
TDG Global Investment JSC
VN:TDG
|
VN |
|
Obic Business Consultants Co Ltd
TSE:4733
|
JP |
|
Y
|
Yaizu Suisankagaku Industry Co Ltd
TSE:2812
|
JP |
|
Shenzhen Cereals Holdings Co Ltd
SZSE:000019
|
CN |
|
Q
|
QubicGames SA
WSE:QUB
|
PL |
|
T
|
Twentyfirst Century Management Services Ltd
NSE:21STCENMGM
|
IN |
|
Razer Inc
HKEX:1337
|
US |
|
T
|
Tailam Tech Construction Holdings Ltd
HKEX:6193
|
CN |
|
A
|
Aeon Hokkaido Corp
TSE:7512
|
JP |
|
Cranswick PLC
LSE:CWK
|
UK |
|
CHAPTERS Group AG
XETRA:CHG
|
DE |
|
Bawan Company SJSC
SAU:1302
|
SA |
|
A
|
Alphabet Inc
XETRA:ABEA
|
US |
|
Ride On Express Holdings Co Ltd
TSE:6082
|
JP |
|
WiseTech Global Ltd
ASX:WTC
|
AU |
|
OS Co Ltd
TSE:9637
|
JP |
|
JSR Corp
TSE:4185
|
JP |
|
Zhejiang Lante Optics Co Ltd
SSE:688127
|
CN |
|
AGM Group Holdings Inc
NASDAQ:AGMH
|
HK |
Uniphar PLC
Uniphar Plc engages in the provision of pre-wholesale and wholesale pharmaceutical distribution. The company is headquartered in Dublin, Dublin and currently employs 2,920 full-time employees. The company went IPO on 2019-07-17. The firm is a diversified healthcare services company. The company serves multinational pharmaceutical and medical technology manufacturers across three divisions: Commercial & Clinical, Product Access and Supply Chain & Retail. Through commercial & clinical division, the Company provides sales, marketing and distribution solutions to multinational pharmaceutical and medical device manufacturers on an outsourced basis. Product Access division offers two service offerings: On Demand Access and Exclusive Access. On Demand Access is a pharmacy led solutions for sourcing and supplying unlicensed medicines to meet the needs of both retail and hospital pharmacists. Exclusive Access is a manufacturer led solution for controlling the release of specialty medicines for specifically approved patient populations. Supply Chain & Retail provides both pre-wholesale distribution and wholesale distribution of pharmaceutical, healthcare and animal health products.
Uniphar Plc engages in the provision of pre-wholesale and wholesale pharmaceutical distribution. The company is headquartered in Dublin, Dublin and currently employs 2,920 full-time employees. The company went IPO on 2019-07-17. The firm is a diversified healthcare services company. The company serves multinational pharmaceutical and medical technology manufacturers across three divisions: Commercial & Clinical, Product Access and Supply Chain & Retail. Through commercial & clinical division, the Company provides sales, marketing and distribution solutions to multinational pharmaceutical and medical device manufacturers on an outsourced basis. Product Access division offers two service offerings: On Demand Access and Exclusive Access. On Demand Access is a pharmacy led solutions for sourcing and supplying unlicensed medicines to meet the needs of both retail and hospital pharmacists. Exclusive Access is a manufacturer led solution for controlling the release of specialty medicines for specifically approved patient populations. Supply Chain & Retail provides both pre-wholesale distribution and wholesale distribution of pharmaceutical, healthcare and animal health products.
Strong Results: Uniphar delivered solid H1 2025 results with revenue of €1.5 billion, gross profit of €220 million, and EBITDA of €58 million.
Profit Growth: Organic gross profit grew by 8%, and earnings per share increased by 21%.
Investments Impact Margins: Upfront investments in technology, management, and new distribution centers are weighing on short-term EBITDA, notably in the Supply Chain & Retail division.
Divisional Performance: Pharma and Medtech divisions reported double-digit and high single-digit profit growth, respectively, while Supply Chain & Retail experienced modest profit growth but lower EBITDA due to investment.
Guidance & Outlook: Management reaffirmed confidence in double-digit growth for Pharma and high single-digit growth for Medtech, with expectations for overall stronger performance in H2 and medium-term EBITDA of €200 million by 2028.
Major Facility Investments: The new Irish distribution center will cost 10–15% more than previously planned, but is expected to quickly surpass return on capital targets and transform operational efficiency.
Geographic Expansion: Growth initiatives include expanding Medtech into the Nordics and Austria and scaling Pharma services in Europe and the U.S.
